Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a drug targeting castrate-resistant prostate cancer, to include Huntsman Cancer Institute. The trial, which is partly funded by the National Cancer Institute, is investigating ENV105 in combination with apalutamide, an existing prostate cancer treatment. This expansion aims to broaden the patient population and identify biomarkers to predict treatment response.
This expansion is crucial for advancing ENV105’s development and understanding its potential in a wider patient group. Including a prestigious institution like Huntsman Cancer Institute adds significant credibility to the study, attracting attention from the medical community and potentially facilitating future collaborations. Identifying predictive biomarkers is essential for personalized medicine, allowing clinicians to select patients most likely to benefit from ENV105 and avoid unnecessary treatment in those less likely to respond.
The Phase 2 trial is evaluating ENV105’s ability to reverse drug resistance in prostate cancer patients by targeting CD105, a protein associated with resistance to standard therapies. The collaboration with multiple clinical sites allows for a more diverse patient sample, improving the generalizability of the findings. The inclusion of Huntsman Cancer Institute further strengthens the study’s scientific rigor.
This expansion signals growing momentum for ENV105 and strengthens Kairos Pharma’s position in developing targeted cancer therapies. The data generated from this expanded trial will be instrumental in guiding future clinical development, informing potential regulatory strategies, and ultimately determining the drug’s potential impact on patients with castrate-resistant prostate cancer. The identification of predictive biomarkers could significantly improve patient outcomes and potentially expand ENV105’s application in other cancer types.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
